Nicolau Syndrome After Glatiramer Acetate Injection in Close Proximity to Administration of SARS-CoV-2 mRNA Vaccine

Neurol Neuroimmunol Neuroinflamm. 2021 Nov 10;9(1):e1112. doi: 10.1212/NXI.0000000000001112. Print 2022 Jan.

Authors

Michael Yu Sy¹, Erin Fromm², Linda Doan², Nathan Rojek², Alexander Ulrich Brandt²

Affiliations

¹ From the Department of Neurology (M.Y.S., E.F., U.B), Department of Pathology (L.D.), and Department of Dermatology (N.R.), University of California, Irvine. msy@hs.uci.edu.
² From the Department of Neurology (M.Y.S., E.F., U.B), Department of Pathology (L.D.), and Department of Dermatology (N.R.), University of California, Irvine.

No abstract available

Publication types

Case Reports

MeSH terms

2019-nCoV Vaccine mRNA-1273
BNT162 Vaccine
COVID-19 / prevention & control*
COVID-19 Vaccines / administration & dosage*
COVID-19 Vaccines / adverse effects*
Female
Glatiramer Acetate / administration & dosage*
Glatiramer Acetate / adverse effects*
Glatiramer Acetate / therapeutic use
Humans
Immunization, Secondary
Immunosuppressive Agents / administration & dosage
Immunosuppressive Agents / adverse effects
Injections / adverse effects*
Injections / methods
Male
Middle Aged
Multiple Sclerosis / therapy
Nicolau Syndrome / complications*
Nicolau Syndrome / pathology*
SARS-CoV-2*

Substances

COVID-19 Vaccines
Immunosuppressive Agents
Glatiramer Acetate
2019-nCoV Vaccine mRNA-1273
BNT162 Vaccine